Introduction {#s0005}
============

A novel SARS-like coronavirus (SARS-CoV-2) is currently emerging and rapidly spreading in humans; to cease this pandemic is to understand how the virus could infect host human cells. Coronavirus spike (S) glycoproteins promote entry into cells via interaction with angiotensin-converting enzyme 2 (ACE-2) [@b0005]. The ACE-2 receptor is expressed unevenly in many human tissues [@b0010]. The crystal structure of the SARS-CoV-2 receptor binding domain in complex with Human ACE-2 was determined [@b0015]. The present article suggests a therapeutic approach to inhibit this interaction and refrain this infection.

The hypothesis {#s0010}
==============

We should design a molecule that has the same affinity of ACE-2 to S protein; in a manner that the formed complex of its combination to S protein will be eliminated from the body. To that end, the author thought to produce a recombinant human protein constituted of two main parts with two possible designs ([Fig. 1](#f0005){ref-type="fig"} -A).Fig. 1Recombinant protein proposed designs and their pathways to induce SARS-CoV-2 phagocytosis The recombinant human protein is constituted of two main parts; the first represent the extracellular domain (ectodomain) of human ACE2 which is in a soluble form, the second is an opsonin molecule which is either the human C3b protein fragment (A-a), or the Fc fragment/CH1 domain of human IgG (A-b). The conjugated molecule targets S protein and inhibits its attachment to ACE-2 receptor on epithelial cells of respiratory or gastrointestinal tract (B). The immune complex generated by the recombinant protein two forms: ACE-2 + C3b and ACE-2 + FcIgG (and transported by RBCs) that enhance its phagocytosis with two distinct pathways: direct and indirect respectively.

Evaluation and discussion of the idea impact {#s0015}
============================================

The designed structures can not only target the virus by covering its surface and preventing its attachment to ACE-2 receptor ([Fig. 1](#f0005){ref-type="fig"}-B) but also opsonizing and enhancing phagocytosis with two distinct pathways, directly and indirectly ([Fig. 1](#f0005){ref-type="fig"}-C). The direct pathway is mediated by the C3b fragment (the larger of two elements formed by the cleavage of complement component 3) that binds to its receptor CR1 (CD35) expressed on red blood cells (RBCs) surface, RBCs transport the complex to the reticuloendothelial system (RES)/mononuclear phagocyte system (MPS) (liver, spleen, kidney, peyer\'s patches, bone morrow...etc.) to be phagocytized. The indirect pathway is activated by the Fc/CH1 domain of human IgG that binds to C3b, this later combines to its receptor expressed on RBCs surface, RBCs transport the complex to the RPS/ MPS to be phagocytized and eliminated. The receptor of Fc-IgG (RFc-IgG) and CR1 located on phagocyte surface help them to receive the complex. Within clinical administration of these molecules, they will imminently enter in competition with ACE-2 receptor for binding to S viral protein, the adaptation of an optimal dose (of these recombinant proteins) have to be taking into account to avoid this competition and rapidly overcoming the virus. In order to promote the indirect pathway, the blood C3b amount should be sufficient to convey the immune complex towards lymphoid tissues via RBCs, therefore we could simultaneously inject human C3b to ensure the activation of this pathways. In the other hand, this may prevent the deposit of the immune complex on some preferred tissues according to their high affinity or high blood pressure. This approach has many advantages that are briefly summarized ([Table 1](#t0005){ref-type="table"} ).Table 1Advantages of the suggested recombinant protein.AdvantageExplanationGain of specificity at 100%The use of ACE-2 ectodomain guaranties the same binding affinityIt avoids side effectsNo chemical compound unlike drugsIt is based on innate immune system reactionsOpsonization and phagocytosisIt doesn't create a cross reactivity of the immune system against the recombinant proteinBoth of proteins are human; part of the bodyIt doesn't require many technologies neither a lot of stagesMonoclonal antibodies production holds many steps and take more timeIt could be applied for eventual new receptors engaged as an entry way of SARS-CoV-2The ectodomain will be changed according to the new receptor
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The following are the Supplementary data to this article:Supplementary data 1

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.mehy.2020.110108>.
